Darrell White
Overview
Explore the profile of Darrell White including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lancman G, Song K, White D, Crosbie T, Sharif I, Emond M, et al.
Front Oncol
. 2024 Dec;
14:1446995.
PMID: 39659785
Background: T-cell-redirecting therapies, such as bispecific antibodies and chimeric antigen receptor T-cells, exploit the cytotoxic capabilities of the immune system to destroy cells expressing specific surface antigens, including malignant cells....
2.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner C, et al.
Cancer Med
. 2024 Nov;
13(21):e70332.
PMID: 39499045
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods: We explored disease characteristics, treatments, and...
3.
McCurdy A, Reece D, Louzada M, White D, Parkin S, Chu M, et al.
Blood Cancer J
. 2024 Sep;
14(1):155.
PMID: 39261451
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line...
4.
Venner C, Duggan P, Song K, Reece D, Sharma S, Su J, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):889-901.
PMID: 38971462
In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem...
5.
Kaedbey R, Reece D, Venner C, McCurdy A, Su J, Chu M, et al.
EJHaem
. 2024 Jun;
5(3):474-484.
PMID: 38895063
Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study aims to evaluate the outcomes in newly...
6.
White D, Schiller G, Madan S, Lentzsch S, Chubar E, Lavi N, et al.
Front Oncol
. 2024 Jun;
14:1352281.
PMID: 38826786
Objective: To identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd). Methods: An analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and...
7.
Trudel S, McCurdy A, Louzada M, Parkin S, White D, Chu M, et al.
Nat Med
. 2024 Jan;
30(2):543-551.
PMID: 38177852
Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies and combinations are therefore required...
8.
Richardson P, Facon T, Venner C, Bahlis N, Offner F, White D, et al.
EJHaem
. 2023 Nov;
4(4):995-1005.
PMID: 38024593
Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration...
9.
Cote J, LeBlanc R, Mian H, Chu M, McCurdy A, Masih-Khan E, et al.
Blood Cancer J
. 2023 Sep;
13(1):137.
PMID: 37669949
Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we...
10.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda V, Su J, Masih-Khan E, et al.
Blood Cancer J
. 2023 Aug;
13(1):129.
PMID: 37635183
No abstract available.